About RHECADIS
The inadequate diagnosis and prognosis of prostate cancer is still a major problem in the detection and treatment of this disease. Unique test systems based on specific biomarkers such as RE-Bx, PRO-Tx, and PRO-Bx precisely address the deficiencies and establish RHECADIS as a leading service provider in cancer molecular diagnostics.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Advertisement
